The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan

Yonemoto, Tsukasa; Hosono, Ako; Iwata, Shintaro; Kamoda, Hiroto; Hagiwara, Yoko; Fujiwara, Tomohiro; Kawai, Akira; Ishii, Takeshi

doi:10.1007/s10147-014-0729-8

Cited by 11 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A later study reported that radiation-induced secondary osteosarcoma proved to have similar outcomes to primary osteosarcoma 33 . However, a recent study suggested that the prognosis of secondary osteosarcoma may be more favorable than that of primary osteosarcoma 34 . The survival and prognostic factors of secondary osteosarcoma remain unclear.…”

Section: Discussionmentioning

confidence: 99%

A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy

Liu

Wang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The prognostic factors for survival among patients with secondary osteosarcoma remain unclear. The aim of this study was to develop a practical nomogram for predicting cancer-specific survival (CSS) in patients with osteosarcoma as a secondary malignancy. The surveillance, epidemiology, and end results database was used for the identification of osteosarcoma cases. The total sample comprised 5860 cases of primary osteosarcoma and 268 cases of secondary osteosarcoma during the period from 1973 to 2015. The CSS and overall survival (OS) of primary and secondary osteosarcomas were analyzed. The predictors of CSS for secondary osteosarcoma were identified and integrated to build a nomogram. Validation of the nomogram was performed using concordance index (C-index) and calibration plots. The results indicated that patients with secondary osteosarcoma had poorer CSS and OS than patients with primary osteosarcoma. The nomogram model exhibited high discriminative accuracy in the training cohort (C-index = 0.826), which was confirmed in the internal validation cohort (C-index = 0.791). In addition, the calibration plots confirmed good concordance for prediction of CSS at 3, 5, and 10 years. In conclusion, we developed a practical nomogram that provided individual predictions of CSS for patients with secondary osteosarcoma. This nomogram may help clinicians with prognostic evaluations and with the development of individualized therapies for this aggressive disease.

show abstract

Section: Discussionmentioning

confidence: 99%

A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy

Liu

Wang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, the survival rate for osteosarcomas is only 50% to 80% despite with an intensive chemotherapy. Numerous efforts have been made to elucidate the mechanisms of osteosarcoma and to develop novel therapeutic strategies [1,2]. Cell growth and division cycle were carefully controlled in normal tissues, thereby ensuring a homeostasis of cell number and thus maintenance of normal tissue architecture and function.…”

Section: Introductionmentioning

confidence: 99%

Osthole Induces Cell Cycle Arrest and Inhibits Migration and Invasion via PTEN/Akt Pathways in Osteosarcoma

Wang

Lei

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Osteosarcoma is the second highest cause of cancer-related death in children and adolescents. Majority of osteosarcoma patients (90%) show metastasis. Previous reports revealed that osthole showed antitumor activities via induction of apoptosis and inhibition of proliferation. However, the potential effects and detailed molecular mechanisms involved remained unclear. Methods: Cell viability was analyzed by MTT assay in osteosarcoma cell lines MG-63 and SAOS-2. Cell cycle was detected by flow cytometry. The effects of migration and invasion were evaluated by wound healing assay and transwell assays. Moreover, the level of proteins expression was determined by Western blot. Results: The cell viability of MG63 and SAOS-2 were markedly inhibited by osthole in a dose- and time-dependent manner. Cell cycle was arrested and the ability of migration and invasion was obviously reduced when cells were exposed to osthole. Moreover, enzymes involved in PTEN/Akt pathway were regulated such as PTEN and p-Akt proteins. Furthermore, osthole inhibited the tumor growth in vivo. Conclusion: Our study unraveled, for the first time, the ability of osthole to suppress osteosarcoma and elucidated the regulation of PTEN/Akt pathway as a signaling mechanism for the anti-tumor action of osthole. These findings indicate that osthole may represent a novel therapeutic strategy in the treatment of osteosarcoma.

show abstract

“…In that study, chemotherapy was administered according to the contemporary Cooperative Osteosarcoma Study Group protocols for secondary osteosarcoma (9), including surgery and multiagent chemotherapy. Furthermore, Yonemoto et al (10) reported that 7 of 9 patients (77.8%) with osteosarcoma as a secondary cancer survived without disease (mean follow-up period, 10.9 years); therefore, the prognosis of osteosarcoma occurring as a secondary malignancy following treatment for childhood cancer may be more favorable compared with that of conventional osteosarcoma.…”

Section: Discussionmentioning

confidence: 99%

Secondary osteosarcoma in patients previously treated for childhood cancer: Three case reports

et al. 2018

View full text Add to dashboard Cite

The prognosis of childhood cancers has improved markedly, and the proportion of long-term survivors has increased in recent years. However, with the increase in the number of long-term survivors, the development of latent treatment-related adverse effects, such as secondary malignancies, has generated new problems. Secondary cancer is defined as a histologically distinct malignancy that develops at least 2 months after the completion of treatment for primary cancer. Genetic factors and acquired conditions associated with treatment modalities are possible causes of secondary malignancy development. Genetic factors include the presence of Li-Fraumeni syndrome (LFS) and retinoblastoma. In terms of acquired factors, radiation and chemotherapy have been reported to be the most strongly associated with secondary malignancy development. The use of alkylating agents and topoisomerase II inhibitors for the treatment of childhood cancer increases the subsequent risk of secondary tumors. We herein investigated three cases of secondary osteosarcoma several years after treatment for primary cancer. In the three patients, the familial history did not appear to fit the clinical diagnostic criteria of LFS or retinoblastoma. The patients had not received previous radiation therapy to the anatomical site of the secondary cancer. However, high dosages of alkylating agents and topoisomerase II inhibitors had been administered for the treatment of primary cancer. The exact link between chemotherapy and secondary cancer remains elusive, but the possibility of an association should be considered. Following the development of multidisciplinary therapies, long-term follow-up and monitoring of latent adverse effects may be necessary for childhood cancer survivors.

show abstract

The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan

Abstract: Attention should be paid to complications of treatment for the first childhood cancer in the treatment for osteosarcoma occurring as second malignancy. The prognosis of osteosarcoma as second malignancy of childhood cancers may be more favorable than that of conventional osteosarcoma.

Cited by 11 publications

References 23 publications

A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy

A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy

Osthole Induces Cell Cycle Arrest and Inhibits Migration and Invasion via PTEN/Akt Pathways in Osteosarcoma

Secondary osteosarcoma in patients previously treated for childhood cancer: Three case reports

Contact Info

Product

Resources

About